Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than 30% of the population, often progressing from reversible steatosis to irreversible fibrosis and cirrhosis. Although cellular senescence is implicated in driving MASLD, the evidence in human tissue and the mechanism are lacking. Here, we apply spatial transcriptomics and scRNAseq to human liver samples spanning healthy to fibrotic disease to address these knowledge gaps. Using a combination of cell stress, cell cycle arrest, extracellular matrix (ECM) remodeling, and inflammatory genes, senescent microenvironments termed "SenSpots" were identified by Visium transcriptomics that predominantly localized to portal tracts and fibrotic septa across all specimens. Functional profiling revealed a fundamental phenotypic divergence: SenSpots in healthy liver displayed a physiological wound-healing and tissue-development program, whereas SenSpots in fibrotic tissue expressed genes related to inflammation, stress, and ECM-disassembly. Spatial deconvolution and network expansion analyses demonstrated that SenSpots act as epicenters for TGF-β, NOTCH, complement, and ECM-reorganization signaling, which spreads into the surrounding tissue microenvironment as disease advances. Furthermore, scRNAseq data validated the Visium results and identified a previously unappreciated population of senescent Schwann cells in the diseased liver niche. These findings map the spatial origination and paracrine propagation of pathological senescence and identify senotypes associated with liver fibrosis.
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: